Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects

ClinicalTrials.gov ID: NCT00840086

Public ClinicalTrials.gov record NCT00840086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-centre, Open-label, Non-controlled Trial on Safety and Efficacy of N8 in Prevention and Treatment of Bleeds in Previously Treated Subjects With Haemophilia A. Sub-trial: Safety and Efficacy of N8 in Prevention and Treatment of Bleeding During Surgical Procedures in Subjects With Haemophilia A

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Asia, Europe, and North and South America. The trial consists of a main trial and a sub-trial. The main trial investigates safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in haemophilia A subjects, while the sub-trial investigates safety and efficacy of turoctocog alfa in prevention and treatment of bleeding episodes during surgical procedures.

Study identification

NCT ID
NCT00840086
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
150 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2009
Primary completion
Aug 31, 2011
Completion
Aug 31, 2011
Last update posted
Mar 16, 2017

2009 – 2011

United States locations

U.S. sites
18
U.S. states
15
U.S. cities
18
Facility City State ZIP Site status
Novo Nordisk Investigational Site Little Rock Arkansas 72202
Novo Nordisk Investigational Site Long Beach California 90806
Novo Nordisk Investigational Site Tampa Florida 33607
Novo Nordisk Investigational Site Atlanta Georgia 30322
Novo Nordisk Investigational Site Augusta Georgia 30912
Novo Nordisk Investigational Site Indianapolis Indiana 46260
Novo Nordisk Investigational Site Iowa City Iowa 52242
Novo Nordisk Investigational Site Omaha Nebraska 68198-2168
Novo Nordisk Investigational Site Newark New Jersey 07102
Novo Nordisk Investigational Site Cincinnati Ohio 45229
Novo Nordisk Investigational Site Dayton Ohio 45404
Novo Nordisk Investigational Site Portland Oregon 97239
Novo Nordisk Investigational Site Philadelphia Pennsylvania 19134-1095
Novo Nordisk Investigational Site Providence Rhode Island 02903
Novo Nordisk Investigational Site Memphis Tennessee 38163
Novo Nordisk Investigational Site Nashville Tennessee 37232-9830
Novo Nordisk Investigational Site Fort Worth Texas 76104
Novo Nordisk Investigational Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 45 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00840086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2017 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00840086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →